Development of an HIV reverse transcriptase aptamer-based detection assay
基于 HIV 逆转录酶适体的检测方法的开发
基本信息
- 批准号:8846946
- 负责人:
- 金额:$ 7.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-12-01 至 2016-11-30
- 项目状态:已结题
- 来源:
- 关键词:AffinityAntibodiesAntibody FormationAntigensAntiviral AgentsBackBase SequenceBindingBiochemicalBiological AssayBiosensorCapsid ProteinsCategoriesCoupledDataDetectionDevelopmentDiagnosticEnzyme-Linked Immunosorbent AssayEquipmentEvolutionFluorescent Antibody TechniqueGelHIVHIV AntibodiesHIV InfectionsHealthHumanIndividualInfectionLaboratoriesLaboratory ScientistsLigandsMethodsMicroscopeModificationMolecular BiologyMonitorNucleic AcidsNucleic acid sequencingNucleotidesPathogen detectionPoly APreclinical Drug EvaluationProteinsRNARNA-Directed DNA PolymeraseRadioactivityScientistScintillation CountingSignal TransductionSourceSpecificityTechnologyTestingTherapeuticTimeVirionVirusVirus DiseasesVirus ReplicationWestern BlottingWorkaptamerbasecostcost effectivedrug resistant virusfallsfollow-upgel electrophoresismodel developmentnanoparticlenext generationoligo (dT)public health relevancerapid detectionreceptorresearch studyscreeningtool
项目摘要
DESCRIPTION (provided by applicant): Detection and quantitation of HIV has been a longstanding issue for scientists and clinicians since the discovery of the virus in 1984. Currentl there are several assays available for screening for HIV infection in the field or the laboratory. They typically fall into a few categories: PCR-based assays that detect HIV RNA, ELISA assays that detect p24 capsid protein, and assays that detect HIV reverse transcriptase (RT). There are also rapid detection screening assays that detect antibodies to HIV and are typically used as the initial screening tests in field assays because of they are highly sensitive and take just minutes to complete. The RT assays though cost effective in most cases, tend to have low sensitivity which is also a drawback of p24 assays. PCR-based assays have high sensitivity but are typically costly and time consuming and require specialized equipment. These assays are also subject to contamination like other PCR assays. The HIV field would benefit from an inexpensive assay that is sensitive, quantitative, fast and simple. An assay that can be performed in a laboratory setting with small quantities of virus and could detect even very low levels of infection that might result from drug screens or mutational analysis. In this application we propose such an assay using aptamer-based technology that we have developed in our lab. Our lab has developed nucleic acid aptamers that can bind to HIV RT with very tightly and are capable of detecting as few as 50-100 virus particles. We have used these aptamers to begin to develop an Aptamer-based RT detection Assay (ARTA) that is sensitive, quantitative, and inexpensive. We envision this technology as the next generation of HIV RT-based detection assays and as a model for development of other aptamer-based pathogen detection assays.
描述(由申请人提供):自1984年发现该病毒以来,HIV的检测和定量一直是科学家和临床医生的长期问题。目前,有几种测定可用于在现场或实验室中筛查HIV感染。它们通常分为几类:检测HIV RNA的基于PCR的测定,检测p24衣壳蛋白的ELISA测定,以及检测HIV逆转录酶(RT)的测定。也有快速检测筛选试验,检测HIV抗体,通常用作现场试验的初始筛选试验,因为它们高度敏感,只需几分钟即可完成。RT测定虽然在大多数情况下是成本有效的,但往往具有低灵敏度,这也是p24测定的缺点。基于PCR的测定具有高灵敏度,但通常昂贵且耗时,并且需要专门的设备。这些测定也像其他PCR测定一样受到污染。艾滋病毒领域将受益于一种灵敏、定量、快速和简单的廉价检测方法。一种可以在实验室环境中使用少量病毒进行的检测方法,甚至可以检测到可能由药物筛选或突变分析导致的非常低水平的感染。在本申请中,我们提出了使用我们在实验室开发的基于适体的技术的这种测定。我们的实验室已经开发出核酸适体,可以非常紧密地与HIV RT结合,并且能够检测到少至50-100个病毒颗粒。我们已经使用这些适体来开始开发基于适体的RT检测测定(阿尔塔),其是灵敏的、定量的和廉价的。我们设想这种技术作为下一代的艾滋病毒RT为基础的检测方法,并作为一个模型,为其他适配体为基础的病原体检测方法的发展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEFFREY J DESTEFANO其他文献
JEFFREY J DESTEFANO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEFFREY J DESTEFANO', 18)}}的其他基金
Using new Next Generation Sequencing (NGS) approaches to analyze the fidelity of HIV reverse transcription in Endogenous Reverse Transcription reactions (ERT)
使用新的下一代测序 (NGS) 方法来分析内源性逆转录反应 (ERT) 中 HIV 逆转录的保真度
- 批准号:
10759845 - 财政年份:2023
- 资助金额:
$ 7.6万 - 项目类别:
Development and Evaluation of Novel Aptamer-based Therapeutics Targeting SARS-CoV-2 in a Physiologically-Relevant Model of Human Airway Epithelium
在人类气道上皮生理相关模型中针对 SARS-CoV-2 的新型适体疗法的开发和评估
- 批准号:
10449392 - 财政年份:2021
- 资助金额:
$ 7.6万 - 项目类别:
Development and Evaluation of Novel Aptamer-based Therapeutics Targeting SARS-CoV-2 in a Physiologically-Relevant Model of Human Airway Epithelium
在人类气道上皮生理相关模型中针对 SARS-CoV-2 的新型适体疗法的开发和评估
- 批准号:
10287842 - 财政年份:2021
- 资助金额:
$ 7.6万 - 项目类别:
Biochemistry of HIV reverse transcriptase fidelity and inhibitor interactions
HIV逆转录酶保真度和抑制剂相互作用的生物化学
- 批准号:
9538330 - 财政年份:2016
- 资助金额:
$ 7.6万 - 项目类别:
Biochemistry of HIV reverse transcriptase fidelity and inhibitor interactions
HIV逆转录酶保真度和抑制剂相互作用的生物化学
- 批准号:
9064995 - 财政年份:2016
- 资助金额:
$ 7.6万 - 项目类别:
MECHANISM OF RECOMBINATION BY HIV REVERSE TRANSCRIPTASE
HIV逆转录酶的重组机制
- 批准号:
2189459 - 财政年份:1994
- 资助金额:
$ 7.6万 - 项目类别:
MECHANISM OF RECOMBINATION BY HIV REVERSE TRANSCRIPTASE
HIV逆转录酶的重组机制
- 批准号:
2701621 - 财政年份:1994
- 资助金额:
$ 7.6万 - 项目类别:
MECHANISM OF RECOMBINATION BY HIV REVERSE TRANSCRIPTASE
HIV逆转录酶的重组机制
- 批准号:
6627193 - 财政年份:1994
- 资助金额:
$ 7.6万 - 项目类别:
Mechanism of recombination by HIV reverse transcriptase
HIV逆转录酶重组机制
- 批准号:
7028364 - 财政年份:1994
- 资助金额:
$ 7.6万 - 项目类别:
MECHANISM OF RECOMBINATION BY HIV REVERSE TRANSCRIPTASE
HIV逆转录酶的重组机制
- 批准号:
6490080 - 财政年份:1994
- 资助金额:
$ 7.6万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 7.6万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 7.6万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 7.6万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 7.6万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 7.6万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 7.6万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 7.6万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 7.6万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 7.6万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 7.6万 - 项目类别:














{{item.name}}会员




